Valuation: Alvotech

Market Cap 2.05B 1.8B 1.71B 1.55B 2.91B 197B 2.92B 20.44B 7.89B 101B 7.7B 7.54B 323B P/E 2026 *
111x
P/E 2027 * 19.4x
Enterprise Value 3.13B 2.75B 2.6B 2.36B 4.43B 300B 4.46B 31.16B 12.03B 153B 11.75B 11.49B 493B EV / Sales 2026 *
4.75x
EV / Sales 2027 * 4.01x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week-1.02%
Current month+11.95%
1 month+19.06%
3 months+57.88%
6 months+86.82%
Current year+13.26%
1 week 5.67
Extreme 5.67
6.06
1 month 4.9
Extreme 4.9
6.06
Current year 2.94
Extreme 2.94
6.06
1 year 2.94
Extreme 2.94
9.04
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 2026-02-28
Director of Finance/CFO 48 2025-07-09
Chief Tech/Sci/R&D Officer - 2022-12-31
Director TitleAgeSince
Chairman 56 2018-12-31
Director/Board Member 64 2018-12-31
Director/Board Member 58 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
4/1/26 Free

Chief Executive Officer

117,271 0.0355%
4/1/26 Sell

Founder

318,000 0.0963%
4/1/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+5.68%-1.02%-30.34%-35.01% 2.05B
+2.64%+7.07%+11.87%+38.40% 47.97B
+0.14%+0.43%+49.97%+37.09% 44.5B
-1.50%+4.51%+337.29%+613.39% 43.93B
+1.62%+0.26%+10.15%+99.06% 41.03B
+0.51%-0.61%+5.18%+46.87% 29.85B
-0.17%-0.94%+23.48%+150.99% 17.27B
-0.70%+8.87%+8.12% - 15.34B
+1.76%+2.98%+29.13%+45.78% 15.3B
+2.03%-3.17% - - 14.82B
Average +0.55%+3.10%+49.43%+124.57% 27.21B
Weighted average by Cap. +0.64%+3.02%+74.23%+161.79%

Financials

2026 *2027 *
Net sales 659M 580M 548M 497M 934M 63.29B 939M 6.57B 2.54B 32.3B 2.48B 2.42B 104B 776M 682M 645M 585M 1.1B 74.46B 1.11B 7.72B 2.98B 37.99B 2.91B 2.85B 122B
Net income 30.36M 26.7M 25.25M 22.9M 43.01M 2.91B 43.26M 302M 117M 1.49B 114M 112M 4.78B 109M 95.96M 90.74M 82.3M 155M 10.47B 155M 1.09B 420M 5.34B 410M 401M 17.17B
Net Debt 1.08B 947M 896M 812M 1.53B 103B 1.53B 10.72B 4.14B 52.75B 4.04B 3.96B 170B 1.06B 930M 879M 797M 1.5B 101B 1.51B 10.53B 4.07B 51.78B 3.97B 3.88B 166B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
26-09-22 US$5.810 -0.51% 773,665
26-09-28 US$6.150 +6.96% 1,432,900
26-09-25 US$5.750 -2.21% 705,189
26-09-24 US$5.880 +1.20% 1,198,733
26-09-23 US$5.810 -0.51% 774,267
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.750USD
Average target price
6.800USD
Spread / Average Target
+18.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock